<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2333">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330300</url>
  </required_header>
  <id_info>
    <org_study_id>C.A. 2348</org_study_id>
    <nct_id>NCT04330300</nct_id>
  </id_info>
  <brief_title>Coronavirus (COVID-19) ACEi/ARB Investigation</brief_title>
  <acronym>CORONACION</acronym>
  <official_title>The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Ireland, Galway, Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University of Ireland, Galway, Ireland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe
      acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is known to require
      the angiotensin-converting enzyme 2 (ACE-2) receptor for uptake into the human body, there
      have been questions about whether medications that upregulate ACE-2 receptors might increase
      the risk of infection and subsequent complications. One such group of medications are
      anti-hypertensives that block the renin-angiotensin system, including both angiotensin
      converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB). Both ACEi and
      ARB are widely used for the treatment of hypertension. Early reports from China and Italy
      suggest that many of those who die from COVID-19 have a coexisting history of hypertension.
      Consequently, there have been questions raised as to whether these 2 types of blood pressure
      medication might increase the risk of death among patients with COVID-19. However, it is well
      known that the prevalence of hypertension increases linearly with age. Therefore, it is
      possible that the high prevalence of hypertension and ACEi/ARB use among persons who die from
      COVID-19 is simply confounded by age (older people are at risk of both a history of
      hypertension and dying from COVID-19). Whether these commonly prescribed blood pressure
      medications increase the risk of COVID-19 or not remains unanswered. Statements from
      professional cardiology societies on both sides of the Atlantic have called for urgent
      research into this question. Our study aims to randomize patients with primary (essential)
      hypertension who are already taking ACEi/ARB to either switch to an alternative BP medication
      or continue with the ACEi/ARB that they have already been prescribed. Adults with compelling
      indications for ACEi/ARB will not be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Challenges with funding and very low incidence of COVID-19 at Irish study site
  </why_stopped>
  <start_date type="Actual">April 30, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)</measure>
    <time_frame>12 months</time_frame>
    <description>Time from randomization to the first occurrence of any of the clinical events above</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Covid-19 positive participants who die</measure>
    <time_frame>12 months</time_frame>
    <description>Time from randomization to the first occurrence of above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Covid-19 positive participants who require intubation in intensive care unit (ICU)</measure>
    <time_frame>12 months</time_frame>
    <description>Time from randomization to the first occurrence of above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV)</measure>
    <time_frame>12 months</time_frame>
    <description>Time from randomization to the first occurrence of above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of SARS-CoV-2 positive participants</measure>
    <time_frame>12 months</time_frame>
    <description>Time from randomization to the first occurrence of above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour mean systolic BP (mmHg) on ambulatory BP monitoring</measure>
    <time_frame>12 months</time_frame>
    <description>Performed in a random sub-sample of the cohort (both study arms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Time from randomization to the first occurrence of above</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2414</enrollment>
  <condition>Hypertension</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Alternative anti-hypertensive medication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Switch to an alternative BP medication (specifically a Calcium channel blocker [CCB] or Thiazide/Thiazide-like diuretic at an equipotent blood pressure lowering dose). The choice of either CCB or Thiazide/Thiazide-like anti-hypertensive provided as alternative therapy will be at the discretion of the patient's treating physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continue ACEi/ARB antihypertensive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continue with either the ACEi (Angiotensin Converting Enzyme Inhibitor) or the Angiotensin Receptor Blocker (ARB) that had already been prescribed for the treatment of hypertension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiazide or Thiazide-like diuretics</intervention_name>
    <description>Anti-hypertensive (Active Arm)</description>
    <arm_group_label>Alternative anti-hypertensive medication</arm_group_label>
    <other_name>Hydrochlorothiazide, metolazone, chlorthalidone, chlorothiazide, bendroflumethiazide, indapamide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Channel Blockers</intervention_name>
    <description>Anti-hypertensive (Active Arm)</description>
    <arm_group_label>Alternative anti-hypertensive medication</arm_group_label>
    <other_name>Amlodipine, diltiazem, felodipine, nicardipine, nifedipine, nimodipine, nitrendipine, verapamil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE inhibitor</intervention_name>
    <description>Anti-hypertensive (Control Arm)</description>
    <arm_group_label>Continue ACEi/ARB antihypertensive</arm_group_label>
    <other_name>Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin receptor blocker</intervention_name>
    <description>Anti-hypertensive (Control Arm)</description>
    <arm_group_label>Continue ACEi/ARB antihypertensive</arm_group_label>
    <other_name>Candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and non-pregnant women aged 60 or over

          -  Known diagnosis of hypertension

          -  Current use of ACEi or ARB for the treatment of hypertension

          -  COVID-19 na√Øve (i.e. not known to be infected)

          -  English speaker

        Exclusion Criteria:

          -  Known diabetic nephropathy

          -  Known heart failure with reduced ejection fraction

          -  Resistant hypertension (defined as blood pressure that remains above goal despite
             concurrent use of three anti-hypertensive agents of different classes, one of which
             should be a diuretic, or as blood pressure that is controlled with four or more
             medications)

          -  Contraindications or allergies to CCB or Thiazide

          -  Unconscious patients

          -  Current psychiatric in-patients

          -  Patients in an emergency medical setting

          -  Inability to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John William McEvoy, MBBCh MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University of Ireland, Galway, Ireland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Galway</name>
      <address>
        <city>Galway</city>
        <zip>H91 YR71</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Ireland, Galway, Ireland</investigator_affiliation>
    <investigator_full_name>Prof. John William McEvoy</investigator_full_name>
    <investigator_title>Professor of Preventive Cardiology</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Blood Pressure</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus Disease 2019</keyword>
  <keyword>Novel Coronavirus</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Pandemic</keyword>
  <keyword>Critical Care</keyword>
  <keyword>Intubation</keyword>
  <keyword>Noninvasive Ventilation</keyword>
  <keyword>Angiotensin Converting Enzyme</keyword>
  <keyword>Angiotensin Converting Enzyme 2</keyword>
  <keyword>Renin-Angiotensin System</keyword>
  <keyword>Antihypertensive Agents</keyword>
  <keyword>Angiotensin-Converting Enzyme Inhibitors</keyword>
  <keyword>Angiotensin Receptor Antagonists</keyword>
  <keyword>Calcium Channel Blockers</keyword>
  <keyword>Diuretics</keyword>
  <keyword>ACE-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Verapamil</mesh_term>
    <mesh_term>Felodipine</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
    <mesh_term>Perindopril</mesh_term>
    <mesh_term>Benazepril</mesh_term>
    <mesh_term>Captopril</mesh_term>
    <mesh_term>Nicardipine</mesh_term>
    <mesh_term>Indapamide</mesh_term>
    <mesh_term>Quinapril</mesh_term>
    <mesh_term>Nimodipine</mesh_term>
    <mesh_term>Trandolapril</mesh_term>
    <mesh_term>Metolazone</mesh_term>
    <mesh_term>Fosinopril</mesh_term>
    <mesh_term>Eprosartan</mesh_term>
    <mesh_term>Nitrendipine</mesh_term>
    <mesh_term>Chlorothiazide</mesh_term>
    <mesh_term>Bendroflumethiazide</mesh_term>
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>12-24 months</ipd_time_frame>
    <ipd_access_criteria>To be determined</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

